共 399 条
[21]
de Braud F(2011)Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2103-3143
[22]
Schuch G(2010)Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial World J Gastroenterol 16 3133-1679
[23]
Zubel A(2012)Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials Ann Oncol 23 1672-5232
[24]
Celik I(2004)Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human tumor xenograft models Proc Am Soc Clin Oncol 45 Abstract 5353-216
[25]
Schlichting M(2007)Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225-iii9
[26]
Koralewski P(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-2019
[27]
Bokemeyer C(2014)Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii1-639
[28]
Bondarenko I(2011)Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011-undefined
[29]
Makhson A(2006)Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)±cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results J Clin Oncol 24 Abstract 3509-undefined
[30]
Hartmann JT(2014)Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial Lancet Oncol 15 631-undefined